Sonoma PharmaceuticalsSNOA
About: Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Employees: 171
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.58% less ownership
Funds ownership: 2.08% [Q3] → 1.5% (-0.58%) [Q4]
31% less funds holding
Funds holding: 13 [Q3] → 9 (-4) [Q4]
37% less capital invested
Capital invested by funds: $85.7K [Q3] → $54.2K (-$31.4K) [Q4]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Research analyst outlook
We haven’t received any recent analyst ratings for SNOA.
Financial journalist opinion









